Nano cap Genprex (GNPX +28.6%) is up on more than double normal volume in reaction to its agreement with the University of Pittsburgh for exclusive rights to a gene therapy for the potential cure of type 1 and type 2 diabetes.
The gene therapy acts by reprogramming alpha cells
in the pancreas into beta-like cells, restoring their function and
increasing insulin levels.
The company plans to pursue development partners globally.
Financial terms are not disclosed.
https://seekingalpha.com/news/3540550-genprex-up-29-on-license-for-diabetes-gene-therapy
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.